Financial Performance - The company's total revenue for 2025 reached ¥274,429,125.09, representing a year-on-year increase of 5.56% compared to ¥259,962,348.72 in 2024[23]. - The total profit for the year was ¥52,063,791.74, which is a 2.66% increase from ¥50,715,759.92 in the previous year[23]. - The net profit attributable to shareholders was ¥45,598,765.68, up 2.19% from ¥44,619,863.78 in 2024[23]. - Basic earnings per share for 2025 were ¥0.68, a 1.49% increase from ¥0.67 in 2024[24]. - The company achieved operating revenue of ¥274,429,125.09, representing a year-on-year growth of 5.56%[54]. - Net profit attributable to shareholders was ¥45,598,765.68, with a year-on-year increase of 2.19%[54]. - The company reported a total operating revenue of RMB 274.43 million for the year 2025, with approximately 50% of this revenue recognized in the fourth quarter, indicating a seasonal revenue pattern[141]. - Total profit for 2025 was ¥52,063,791.74, compared to ¥50,715,759.92 in 2024, reflecting an increase of 2.7%[160]. Cash Flow and Assets - The net cash flow from operating activities significantly increased by 49.50% to ¥76,206,494.95 from ¥50,974,578.88 in 2024[23]. - Cash and cash equivalents at the end of the period amounted to ¥333,787,097.23, representing 32.74% of total assets, up from 28.47%[68]. - The company’s investment activities resulted in a net cash outflow of ¥1,080,600.00, an improvement from the previous year's outflow of ¥6,354,109.48[55]. - The company reported a total current asset of CNY 574.64 million as of December 31, 2025, an increase from CNY 493.22 million in the previous year[150]. - The cash and cash equivalents increased to CNY 333.79 million from CNY 269.92 million year-over-year, reflecting a growth of approximately 23.7%[150]. - The company reported a total operating cash inflow of ¥319,768,922.46, up from ¥280,913,477.70 in the previous period, marking a growth of 14%[165]. Research and Development - Research and development expenses rose by 8.08% to ¥18,589,530.78, accounting for 6.77% of total operating revenue[64]. - The company has developed a series of rapid road condition detection equipment, including multi-functional detection systems and various testing devices, to meet diverse data collection needs[31][34]. - The company is concentrating on R&D in smart detection equipment, green low-carbon materials, and "AI + road maintenance" technologies[79]. - The number of R&D personnel is 68, accounting for 28.45% of the total workforce[65]. - The company has established a talent team of 239 employees, with 55% holding a bachelor's degree or higher, enhancing its innovation capabilities[52]. Market Position and Products - The company’s main business includes highway maintenance decision consulting services, rapid road condition detection equipment production and sales, and highway maintenance information system development and sales[30]. - The company’s products are designed to enhance the efficiency of highway maintenance funding and improve decision-making processes through data analysis[30]. - The company has established a strong market demand for its consulting services, driven by the ongoing transformation of the highway maintenance industry[30]. - The company’s rapid detection equipment has positioned it as a leading player in the niche market of road condition detection[34]. - The sales volume of CiCS series equipment continues to maintain a high market share in the high-end equipment sector[44]. Governance and Management - The company has implemented governance improvements, including the cancellation of the supervisory board and revisions to its articles of association to enhance operational efficiency[84]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[86]. - The company has established several committees, including the Strategy and Development Committee and the Audit Committee, to enhance governance and protect shareholder interests[86]. - The company has implemented measures to ensure the independence of its operations from controlling shareholders[86]. - The company has a structured approach to board meetings, ensuring compliance with relevant laws and regulations[86]. Risks and Challenges - The company faces risks of declining gross margins due to rising operating costs outpacing revenue growth, with a noted trend of decreasing gross margin[80]. - The company acknowledges market competition risks as demand for scientific decision-making systems in road maintenance grows, attracting new entrants[81]. - The company is also facing market development risks due to traditional decision-making mindsets in the road maintenance sector[81]. - The company is at risk of losing core technical personnel to competitors, which could weaken its technological advantages[80]. Shareholder Information - The company distributed a cash dividend of 1.673 RMB per 10 shares, totaling 11,155,564 RMB, which is 30.01% of the net profit attributable to ordinary shareholders[104][106]. - The total compensation for directors and senior management during the reporting period amounted to CNY 5,809,168.83[87]. - The largest shareholder, Zhonglu Gaoke Transportation Technology Group Co., Ltd., holds 30,832,000 shares, representing 46.24% of the total shares[130]. - The company has no significant changes in the top ten shareholders or their shareholding status during the reporting period[131]. Compliance and Audit - The audit opinion confirmed that the financial statements fairly reflect the company's financial position as of December 31, 2025[140]. - The company has established internal controls over sales and receivables processes, which were evaluated during the audit[141]. - The company appointed Zhihong Accounting Firm (Special General Partnership) as the auditor for the 2025 fiscal year, with an audit fee of RMB 300,000[119]. - There were no penalties imposed by securities regulatory authorities in the past three years[94].

Financial Projections - The company expects a total profit of -25 million yuan for the year 2025, with a net profit attributable to shareholders of -29 million yuan and a net profit of -23 million yuan after deducting non-recurring gains and losses [4]. - The anticipated operating revenue for 2025 is 370 million yuan, with 350 million yuan after excluding unrelated business income and income without commercial substance [4]. - The net assets attributable to shareholders are projected to be 80 million yuan by the end of 2025 [4]. - In the previous year, the net profit attributable to shareholders was -136.14 million yuan, with an operating revenue of 175.21 million yuan [5]. Business Strategy - The company implemented a "dual flagship product" strategy focusing on Haiwang liquor and Lugu liquor, which significantly boosted sales revenue compared to the previous year [7]. - The increase in operating losses is attributed to higher marketing and promotional expenses aimed at expanding market share and launching new products [7]. Risk Factors - The company is under risk warning for potential delisting due to negative net profit and revenue concerns, as well as previous audit opinions indicating uncertainty in going concern [8]. - The annual audit firm is currently reviewing the company's terminal sales and return situations, which may affect the audit opinion for 2025 [9]. - If the audited financial report shows negative profit or revenue below 300 million yuan, the company's stock may be delisted following the 2025 annual report disclosure [10]. - The company emphasizes the importance of timely information disclosure and urges investors to pay attention to investment risks [10].

Financial Performance - The company reported a basic earnings per share of RMB 0.236 for 2025, representing a 4.42% increase from RMB 0.226 in 2024[28]. - The company's operating revenue for 2025 reached ¥5,632,950,354.38, representing a 16.29% increase compared to ¥4,843,753,794.70 in 2024[29]. - The net profit attributable to shareholders for 2025 was ¥118,493,733.40, up 4.29% from ¥113,620,696.95 in 2024[29]. - The net profit after deducting non-recurring gains and losses surged by 235.94% to ¥157,620,033.20 from ¥46,919,280.55 in 2024[29]. - The diluted earnings per share for 2025 increased to ¥0.235, a 3.98% rise from ¥0.226 in 2024[30]. - The weighted average return on equity rose to 2.641% in 2025, an increase of 0.177 percentage points from 2.464% in 2024[30]. - The total assets at the end of 2025 were ¥8,458,303,696.37, reflecting a 9.55% increase from ¥7,720,899,535.16 at the end of 2024[29]. - The net cash flow from operating activities for 2025 was ¥459,306,102.23, down 13.46% from ¥530,727,216.06 in 2024[29]. Dividend Policy - The company will not distribute cash dividends for the year 2025 due to negative retained earnings as of the end of the reporting period[9]. - The company has a negative cumulative undistributed profit in its financial statements, which affects its ability to implement cash dividends[10]. Audit and Compliance - The company has received a standard unqualified audit report from KPMG Huazhen[8]. - The company’s board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[6]. Market Position and Strategy - The company has established a leading position in the dairy industry, particularly in cheese products, after ten years of rapid development[43]. - The company aims to expand its product offerings in the cheese sector, focusing on ready-to-eat nutrition series and family dining series[43]. - The cheese business generated revenue of 461,522.73 million yuan in 2025, marking a year-on-year growth of 22.84%, which was the main driver of overall revenue growth[53]. - The market share of the company's cheese products exceeded 38% in 2025, maintaining the leading position in the Chinese packaged cheese market[52]. - The company is benefiting from supportive government policies aimed at promoting healthy consumption and the development of the cheese industry, which are expected to enhance market opportunities[47]. Product Development and Innovation - The company has enhanced its R&D capabilities, collaborating with domestic universities and research institutions, and received multiple awards for product innovation, including the Shanghai Science and Technology Award[62]. - The company launched new products targeting specific consumer groups, such as children's nutrition and adult snacks, expanding its product matrix and consumption scenarios[64]. - The introduction of domestically produced mozzarella cheese marks a significant milestone, filling a market gap and promoting high-quality upgrades in the industry[67]. Operational Efficiency - The company is focusing on cost reduction and efficiency improvement strategies to enhance profitability and sustain growth momentum[53]. - The overall business structure optimization has led to improved operational quality and a positive market outlook[61]. - The company has established a comprehensive supply chain management system, enhancing overall management efficiency and laying a solid foundation for cost reduction and efficiency improvement[73]. Governance and Management - The company has a robust governance structure, with specialized committees to enhance decision-making processes[145]. - The board of directors consists of 9 members, including 3 independent directors, and held 15 meetings during the reporting period[145]. - The company has established a complete and independent financial accounting department, ensuring financial independence[151]. - The company maintains a commitment to transparency, ensuring timely and accurate information disclosure to all shareholders[148]. Risk Management - The company is subject to risks related to its future development, as outlined in the management discussion and analysis section[13]. - Market competition risks are anticipated as both domestic and international brands increase their investments in the cheese sector[137]. - Fluctuations in raw material prices from international markets pose a risk to product profitability and cash flow[138]. - The company prioritizes food safety to mitigate risks associated with public safety events that could impact brand reputation[139]. Employee and Human Resources - The total number of employees in the parent company is 870, while the main subsidiaries employ 2,362, resulting in a total of 3,232 employees[184]. - The professional composition includes 1,608 production personnel, 814 sales personnel, 460 technical personnel, 82 financial personnel, and 268 administrative personnel[184]. - The company has established a comprehensive training management system to enhance talent development and organizational efficiency[187]. Future Outlook - The company provided a positive outlook for the next quarter, projecting a revenue growth of 12% to 15%[167]. - The company plans to acquire 100% equity of Inner Mongolia Mengniu Cheese Co., Ltd. for approximately RMB 447.68 million, resolving competition issues in the cheese sector[158]. - The company aims to increase its cheese market share, with a target of over 38% in the packaged cheese segment by 2025[130].

Financial Performance - In 2025, the company's operating revenue reached CNY 34.55 billion, a 6.40% increase from CNY 32.47 billion in 2024[28]. - The total profit for 2025 was CNY 4.91 billion, reflecting a 3.75% increase compared to CNY 4.73 billion in 2024[28]. - The net profit attributable to shareholders was CNY 3.69 billion, up 5.48% from CNY 3.49 billion in 2024[28]. - The company's total assets at the end of 2025 were CNY 118.32 billion, a slight increase of 0.37% from CNY 117.89 billion in 2024[28]. - The net assets attributable to shareholders increased to CNY 49.84 billion, a 3.79% rise from CNY 48.03 billion in 2024[28]. - The basic earnings per share for 2025 was CNY 0.34, a 6.25% increase from CNY 0.32 in 2024[29]. - The net cash flow from operating activities decreased by 124.71%, primarily due to a significant reduction in customer deposits and cash received from sales[30]. - The company reported a significant decline in net cash flow from operating activities, which was CNY -1.29 billion, a decrease of 124.71% compared to the previous year[121]. - The company achieved a revenue of 10,864.84 million, with a net profit of 1,294.49 million, indicating a strong performance in the current fiscal period[102]. - The revenue for the smart station integration system reached 2,316 million, with a year-on-year growth of 1,059.34 million and 1,321.15 million in user demand optimization[105]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 1.7 per 10 shares, totaling RMB 1,800,269,230, based on a total share capital of 10,589,819,000 shares as of December 31, 2025[6]. - The cash dividend policy was executed with a distribution of RMB 1.7 per 10 shares, amounting to a total cash dividend of RMB 1,800,269,230, which represents 48.84% of the net profit attributable to shareholders[198][200]. - The company plans to distribute cash dividends to all shareholders, with the expected payment date on or before August 31, 2026[198]. Technological Advancements - The company achieved a breakthrough in railway operation control technology, enabling the operation of a 35,000-ton heavy-haul train group, marking a world-first trial[16]. - The company has launched several major technological achievements, including a new operation control system for the Qinghai-Tibet Railway and a new control system based on Beidou positioning[16]. - The company focuses on the rail transit control system and has expanded into low-altitude economy sectors, developing a "1+4" innovation system for low-altitude airspace management[41]. - The company aims to become a world-class intelligent control enterprise, emphasizing the integration of rail and low-altitude sectors for collaborative development[41]. - The company has developed a high-precision simulation technology based on spatial multi-physical field coupling, achieving an error rate within 0.5% for analyzing the transmission characteristics of various typical railway circuit configurations[73]. - The company has developed new core technologies including railway 5G communication systems and intelligent scheduling control technology[82]. - The company has developed a multi-dimensional data analysis theory to optimize resource allocation and improve operational efficiency in urban rail transit systems[103]. - The company has developed advanced technologies for various rail transport sectors, including autonomous train operation and intelligent fault prediction systems, enhancing market competitiveness[109]. Market Expansion - The company has opened up the EU core market with its onboard solutions for railway interoperability in Europe[16]. - The company is actively developing the domestic low-altitude economy market, with significant progress in low-altitude airspace control systems deployed in key cities[61]. - The company aims to enhance its brand influence in the global rail transit market through strategic overseas expansions and successful project implementations[53]. - The company is expanding its market presence in regions D and E, aiming for a market share increase of F% by the end of the fiscal year[168]. - The company is actively pursuing market expansion through the development of multi-standard interoperable train control systems, catering to diverse operational needs[104]. - The company is expanding its international market presence with the mobile block control system, having secured contracts in Guinea for railway signal and train operation control solutions[105]. Research and Development - Research and development expenses accounted for 6.49% of operating revenue, up from 6.28% in 2024[29]. - The company has over 6,000 registered patents, achieving 100% autonomy in core train control technology and products, which supports various rail transit applications[65]. - The company applied for 1,561 new patents this year, including 1,435 invention patents, and received 815 new authorizations, with 693 being invention patents[96]. - The company has invested a total of 18,858.06 million in the new generation dispatch centralized system, with 4,067.06 million allocated in the current period, achieving a cumulative investment of 16,589.29 million[101]. - The company is investing in R&D, allocating $H million to develop next-generation technologies aimed at improving operational efficiency[168]. - The R&D team has increased by 15%, focusing on innovative solutions to meet market demands[172]. Strategic Initiatives - The company is committed to enhancing its capital operation capabilities, focusing on a dual-track development strategy of "industry + capital"[18]. - The company aims to deepen its focus on "rail transit + low-altitude economy" sectors and develop intelligent systems for smart cities and operations[20]. - The company is focusing on enhancing user data analytics capabilities to better understand market trends and customer needs[167]. - The company is dedicated to maintaining high standards of corporate governance and transparency in its operations[167]. - The company is focusing on enhancing its core competencies and has outlined a "1241" development strategy to drive industrial transformation[119]. Awards and Recognition - The company received one Luban Award and 14 provincial and ministerial quality engineering awards for its projects[17]. - The company was recognized as a "Manufacturing Single Champion Enterprise" for its complete set of railway traffic control systems in 2020[85]. - The company has been awarded multiple patents for innovations in railway signal systems and automatic train operation technologies[84]. - The company was recognized as a national-level "Little Giant" enterprise for its specialized and innovative capabilities in the railway sector[85]. Corporate Governance - The company has established a value management system to enhance investment quality and protect shareholder rights[155]. - The company adheres to the compensation management regulations set by the State-owned Assets Supervision and Administration Commission[175]. - The company’s risk management and internal control systems were deemed effective after reviewing accounting policies and practices[185]. - The company plans to implement a diversified policy for board members and senior management, as discussed in the Nomination Committee meetings[187]. Employee Management - The company has established a comprehensive training plan for 2025, focusing on the development of young talents and enhancing professional capabilities[195]. - The company emphasizes a performance-based salary system, linking compensation to economic efficiency and productivity[193]. - The total number of employees in the parent company is 130, while the main subsidiaries employ 19,069, resulting in a total of 19,199 employees[192].

Financial Performance - In 2025, the company achieved operating revenue of RMB 29.05 billion, representing a year-on-year growth of 2.22%[14] - The net profit attributable to shareholders was a loss of RMB 9.26 billion[14] - The net operating cash flow was RMB 1.144 billion[14] - In 2025, the company's revenue was approximately 29.05 billion yuan, a 2.22% increase from 2024, while the net profit attributable to shareholders was a loss of approximately 9.26 billion yuan[24] - The total assets at the end of 2025 were approximately 118 billion yuan, a decrease of 6.05% compared to the end of 2024[24] - The net asset attributable to shareholders decreased by 28.92% year-on-year, amounting to approximately 21.97 billion yuan at the end of 2025[24] - The company's cash flow from operations was 1.144 billion CNY, with net operating cash flow including bank bills at 3.085 billion CNY[36] - The photovoltaic materials segment reported revenue of 12.238 billion CNY, a year-on-year decrease of 26.49%[40] - The photovoltaic battery and module segment achieved revenue of 9.324 billion CNY, a year-on-year increase of 60.45%, with a shipment of 15.1 GW[41] - The semiconductor materials segment generated revenue of 5.707 billion CNY, a year-on-year increase of 21.75%[43] Market Conditions and Competition - The company is facing severe "involution" competition in the photovoltaic industry, with supply and demand still imbalanced and product prices at the bottom[14] - The company acknowledges the uncertainties in global economic growth due to geopolitical conflicts and trade barriers[14] - The global photovoltaic market saw new installations reach 580 GW in 2025, with ongoing supply-demand imbalances[44] - The company emphasizes the importance of market-oriented mergers and acquisitions to break the current competitive deadlock in the industry[14] Strategic Initiatives - The company plans to enhance its silicon wafer business competitiveness and improve its battery module business layout through both internal growth and external mergers and acquisitions[14] - The company aims to implement a moderate integration and globalization strategy to reshape its core capabilities[14] - The company aims to strengthen its core competitiveness and achieve sustainable development by focusing on strategic leadership, innovation-driven growth, advanced manufacturing, and global operations[18] - The company plans to invest 1.06 billion yuan in R&D in 2025, accounting for 3.65% of its revenue, and has a total of 4,763 valid authorized intellectual property rights[16] Research and Development - The company invested 1.06 billion CNY in R&D, accounting for 3.65% of operating revenue[38] - The company has a total of 4,763 valid authorized intellectual properties, including 606 domestic invention patents and 1,992 foreign patents, enhancing its global competitive edge[49] - Research and development expenses rose by 10.31% year-on-year to 825,696,810.67 RMB, reflecting ongoing investment in innovation[64] - The company achieved a production line core diameter reduction of 4um with a process yield exceeding 95% in the fine wire cutting project[66] - The TBC battery cell achieved a conversion efficiency of 26.6%, supporting future industrialization efforts[66] Operational Efficiency - The company aims to enhance operational capabilities and optimize processes to improve efficiency and responsiveness[82] - The company acknowledges risks from market competition and plans to improve product core competitiveness and operational efficiency[84] - The company is aware of the risks associated with raw material price fluctuations and aims to mitigate these through cost reduction strategies[85] - The company will adjust procurement strategies to minimize the impact of raw material price fluctuations on operations[86] Governance and Compliance - The company has a robust internal control system and governance structure, continuously improving operational standards and ensuring shareholder rights are protected[94] - The company emphasizes strict compliance with information disclosure obligations, ensuring the accuracy and completeness of disclosed information[96] - The internal audit mechanism is continuously improved, focusing on the operation of internal controls and financial management[96] - The governance structure has been updated, including revisions to 26 governance documents to enhance compliance and operational effectiveness[97] Human Resources and Talent Development - The total number of employees at the end of the reporting period is 12,598, with 194 in the parent company and 12,404 in major subsidiaries[121] - The company provided over 54,000 hours of training, covering more than 12,000 employees, with 690 training sessions conducted[123] - The company has implemented a structured "mentor-apprentice" mechanism, with over 800 employees receiving training through this program[123] - The company plans to enhance its talent development strategy by adding partnerships with 2 new educational institutions, focusing on systematic educational pathways[124] Shareholder and Investor Relations - The company will not distribute cash dividends or issue bonus shares[5] - The company has established a market value management system and valuation enhancement plan to improve investment value and enhance investor returns, approved by the board in April 2025[90] - The company is actively implementing the "Quality and Return Dual Improvement" action plan to boost investor confidence and promote sustainable development, as disclosed in February 2024[91] Environmental and Social Responsibility - The company aims to integrate sustainable development into its overall strategy, focusing on climate change, resource utilization, and supply chain safety[149] - The company reported that 96.95% of the total assets and 99.85% of the total revenue were included in the internal control evaluation scope[146] - The company achieved a rating upgrade in ESG from BBB to A, becoming one of the few in the photovoltaic industry to receive such a high rating[150] - By 2025, the TCL Public Welfare Foundation has donated solar power systems to 35 schools, with a total installed capacity of 2,054.65 kW, expected to provide approximately 61.91 million kWh of green electricity over 25 years[156]

Financial Performance - Huaneng International's operating revenue for 2025 was approximately RMB 229.29 billion, a decrease of 6.62% compared to RMB 245.55 billion in 2024[21] - The total profit for 2025 reached RMB 23.64 billion, representing a significant increase of 30.73% from RMB 18.09 billion in 2024[21] - Net profit attributable to shareholders for 2025 was RMB 14.41 billion, up 42.17% from RMB 10.14 billion in 2024[21] - The net cash flow from operating activities for 2025 was RMB 67.21 billion, an increase of 33.02% compared to RMB 50.53 billion in 2024[21] - The total assets of the company at the end of 2025 were RMB 611.79 billion, reflecting a growth of 4.25% from RMB 586.84 billion at the end of 2024[22] - The net assets attributable to shareholders increased to RMB 142.47 billion, a rise of 3.68% from RMB 137.41 billion in 2024[22] - Basic earnings per share for 2025 were RMB 0.74, a 61.37% increase from RMB 0.46 in 2024[23] - The weighted average return on equity for 2025 was 19.04%, an increase of 5.90 percentage points from 13.14% in 2024[23] Dividends and Shareholder Returns - The company plans to distribute a dividend of RMB 0.40 per share, amounting to approximately RMB 627.92 million based on 15,698,093,359 shares[5] - The net profit attributable to shareholders of the listed company for the current period is CNY 14,409,553,809, an increase from CNY 10,135,493,813 in the previous period, representing a growth of approximately 42.5%[24] - The total net assets attributable to shareholders at the end of the period reached CNY 142,468,648,190, up from CNY 137,414,784,587 at the beginning of the period, indicating an increase of about 3.9%[24] Revenue and Sales Performance - The operating revenue for the first quarter was CNY 60,334,914,635, while the net profit attributable to shareholders was CNY 4,972,738,942, reflecting a strong performance in Q1[31] - The company achieved operating revenue of RMB 229.29 billion in 2025, a decrease of RMB 16.26 billion, or 6.62%, primarily due to a decline in domestic electricity sales and prices[45] - The average on-grid settlement price for electricity was RMB 477.08 per MWh, a decrease of 3.48% year-on-year[45] - The company completed a total on-grid electricity of 437.563 billion kWh, a year-on-year decrease of 3.39%[45] Cost Management and Efficiency - Operating costs fell by 10.26% year-on-year to CNY 186.99 billion, attributed to enhanced cost control and lower fuel prices[60] - The company’s coal-fired power generation unit sales cost was RMB 266.88 per MWh, down 11.13% year-on-year due to improved coal supply-demand dynamics[40] - The average unit fuel cost for electricity sales decreased by 11.13% year-on-year to CNY 266.88 per MWh[63] Strategic Focus and Future Outlook - The company plans to continue its strategic focus on mergers and acquisitions under the same control, which may affect future financial performance and asset valuations[26] - The company anticipates a 5%-6% year-on-year growth in national electricity consumption by 2026, with total installed capacity expected to exceed 400 million kW[112] - The company aims to achieve an electricity generation of approximately 460 billion kWh in 2026[118] - The company is committed to deepening green and low-carbon transformation, emphasizing the development of large-scale wind and solar bases[115] Research and Development - R&D expenses increased by 15.77% year-on-year to CNY 1.92 billion, reflecting a greater investment in core business development[61] - The company holds 1,359 domestic invention patents and 213 international invention patents as of 2025, reflecting its focus on technological innovation[52] - Total R&D investment amounted to 2.045 billion RMB, representing 0.89% of total operating revenue, with 6.09% of R&D costs capitalized[79] Governance and Compliance - The company has established a governance structure that enhances operational efficiency and market credibility, ensuring compliance with regulatory requirements[53] - The board of directors consists of more than 50% external directors and over 30% independent directors, ensuring a robust governance structure[135] - The company has established a comprehensive governance system to ensure compliance with laws and regulations, enhancing operational efficiency[130] Environmental and Social Responsibility - The company emphasizes the importance of environmental protection and has implemented ultra-low emissions operations across all coal-fired power plants[123] - The company made a total contribution of 4.418 million yuan to external donations and public welfare projects, including disaster relief donations[179] - The company is listed among the top 500 Chinese enterprises for rural revitalization in 2025, enhancing its brand value while contributing to social harmony[181] Management and Personnel - The company employed a total of 56,104 staff, with 8,658 in the parent company and 47,446 in major subsidiaries[160] - The educational background of employees shows 5,318 with postgraduate degrees, 32,434 with bachelor's degrees, 11,064 with associate degrees, and 7,288 with other qualifications[160] - The total compensation for all directors and senior management at the end of the reporting period amounted to 8.539 million yuan[149] Financial Transactions and Audit - The company has changed its domestic accounting firm from Ernst & Young Hua Ming to Lixin CPA, with the audit fee reduced from 23,340,000 RMB to 15,090,000 RMB, a decrease of over 20%[195] - The company has a cash dividend policy that stipulates a minimum distribution of 50% of the annual distributable profit, provided that the company is profitable and has sufficient cash flow[163] - The company received a standard unqualified opinion on its internal control audit report from the external auditor, which aligns with the board's self-assessment[174]

Financial Performance - The company's operating revenue for 2025 reached ¥2,583,927,321.09, representing a 25.08% increase compared to ¥2,065,801,597.74 in 2024[25]. - Total profit for 2025 was ¥936,290,399.51, up 25.51% from ¥745,967,278.53 in 2024[25]. - Net profit attributable to shareholders for 2025 was ¥820,636,582.43, a 21.91% increase from ¥673,151,713.17 in 2024[25]. - The net cash flow from operating activities for 2025 was ¥967,759,658.78, reflecting a 30.18% increase compared to ¥743,390,010.98 in 2024[25]. - The company's total assets as of the end of 2025 were ¥3,651,856,647.08, a 22.52% increase from ¥2,980,697,768.82 at the end of 2024[25]. - Net assets attributable to shareholders at the end of 2025 were ¥3,088,667,057.76, up 22.74% from ¥2,516,339,545.43 at the end of 2024[25]. - The net profit excluding non-recurring gains and losses for 2025 was ¥790,875,930.28, a 23.00% increase from ¥643,008,371.94 in 2024[25]. - Basic earnings per share for 2025 reached CNY 5.82, a 21.25% increase compared to CNY 4.80 in 2024[26]. - Diluted earnings per share for 2025 were CNY 5.80, reflecting a 21.85% growth from CNY 4.76 in 2024[26]. Dividend and Share Repurchase - The company plans to distribute a cash dividend of 10 RMB per 10 shares, totaling approximately 139.16 million RMB, which represents 29.13% of the net profit attributable to shareholders for 2025[6]. - The total amount for cash dividends and share repurchases is approximately 239.08 million RMB, accounting for 29.13% of the net profit attributable to shareholders for 2025[6]. - The company has repurchased 1,869,440 shares, which will not participate in this profit distribution[7]. - The company does not plan to increase capital reserves or issue bonus shares[7]. Corporate Governance - There are no special arrangements for corporate governance or significant matters affecting the company[10]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[10]. - The company has received a standard unqualified audit report from its accounting firm[5]. - The company emphasizes that forward-looking statements do not constitute a commitment to investors and advises caution regarding investment risks[9]. - The company has established a governance structure comprising a shareholder meeting, board of directors, and senior management to ensure compliance and orderly operations[180]. - The board consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements[181]. - The company has implemented measures to maintain the independence of its assets, personnel, and operations from its controlling shareholders[184]. Market and Product Development - The company is focused on expanding its market presence and developing new technologies in the medical device sector[24]. - The company focuses on the research, production, and sales of electrophysiology and interventional medical devices, with a business layout centered on complete coronary access and cardiac electrophysiology products[39]. - The company has launched several innovative products, including the AForcePlusTM three-dimensional linear pressure pulse ablation catheter, which is the first of its kind approved for atrial fibrillation treatment in China[41]. - The company’s electrophysiology products include the three-dimensional cardiac electrophysiology mapping system and various ablation catheters, with several products receiving national recognition as key new products and high-tech products[42]. - The company has developed a comprehensive platform for peripheral vascular interventional devices, with products including drug-eluting microspheres and balloon microcatheters, addressing both tumor embolization and peripheral vascular diseases[46]. - The company has successfully registered a ureteral stent system, becoming the first domestic company to obtain this certification, enhancing its product offerings in the urinary intervention field[47]. - The company is leveraging its technological advancements and cost advantages to strengthen its competitive position in the industry[62]. - The company aims to enhance its product portfolio and create a diversified product matrix to mitigate cyclical risks in single markets[168]. Research and Development - The company has a research and development team of 588 people, accounting for 18.86% of total employees, focusing on various fields such as medicine, engineering, and materials[82]. - The total R&D investment reached approximately ¥364.80 million, representing a 25.56% increase from the previous year, with R&D expenses accounting for 14.12% of total revenue[98]. - The company applied for 22 new invention patents and received 27 grants during the reporting period, reflecting its commitment to innovation and clinical application[95]. - The company is advancing multiple R&D projects, including a new balloon dilation catheter and an abdominal aortic stent system, with significant investments and progress in clinical trials[101]. Risks and Challenges - The company faces risks related to new product development failures and the need for continuous innovation to maintain competitive advantage in the medical device industry[108]. - The company is at risk of declining product prices and gross margins due to ongoing national procurement policies and increased competition in the medical device industry[112]. - The company’s operations are significantly affected by macroeconomic policies and global economic conditions, including international trade tensions and geopolitical uncertainties[121]. - The company is subject to risks associated with product registration, as high-tech medical devices face stringent regulatory requirements that could delay market entry[120]. Sales and Marketing - The sales model primarily utilizes a distribution approach domestically, while international sales are conducted through distributors, ensuring broad market reach[51]. - The company has established a strong OEM business, leveraging its R&D capabilities and core production processes to provide customized manufacturing services[49]. - The company held over 260 brand activities nationwide, covering more than 30 provinces and municipalities, to promote brand awareness and new product launches[74]. - The company is leveraging online and offline integrated marketing strategies to effectively communicate comprehensive product solutions to clinical needs[74]. Compensation and Governance - The total pre-tax compensation for the executives during the reporting period amounted to 1,661.12 million yuan[188]. - The total number of shares held by all executives at the beginning of the year was 21,351,302, which increased to 28,135,714 by the end of the year, representing a net increase of 6,784,412 shares[188]. - The company has no deferred payment arrangements for the compensation of directors and senior management during the reporting period[197]. - The independent directors' allowances are not subject to performance assessment[197].

Financial Performance - The company reported a total revenue of 3,949 million, with a year-over-year increase of 20.67%[176]. - The company achieved a total profit of 280.63 million yuan, a year-on-year increase of 42.81%[82]. - The operating revenue for 2025 reached ¥3,830,067,158.63, representing a 50.39% increase compared to ¥2,546,810,190.04 in 2024[36]. - Net profit attributable to shareholders decreased by 31.80% to ¥158,106,464.15 in 2025 from ¥231,825,227.30 in 2024[36]. - The company's diluted earnings per share decreased by 32.65% to ¥0.33 in 2025 from ¥0.49 in 2024[36]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, which fell by 63.97% to ¥78,172,319.98 in 2025 from ¥216,956,546.69 in 2024[36]. - The company’s investment income for the reporting period was ¥87,118,145.70, accounting for 48.54% of total profit[105]. - The company’s cash flow from operating activities showed a significant decline of 65.87%, totaling ¥161,323,847.26 in 2025 compared to ¥472,623,479.01 in 2024[36]. - The company’s revenue from mainland China was 843.98 million yuan, reflecting a growth of 109.52%[89]. - The revenue from other countries and regions was 2.99 billion yuan, an increase of 39.28%[89]. Market Expansion and Strategy - The company plans to implement an ecological strategy of "deep cultivation and new expansion," focusing on high-growth sectors such as smart hardware and AI-native applications[10]. - Future outlook indicates a projected revenue growth of 15% for the upcoming fiscal year, driven by new product launches and market expansion strategies[31]. - Market expansion efforts include entering three new international markets, aiming for a 20% increase in global market share[31]. - The company plans to pursue strategic acquisitions to enhance its technological capabilities and market presence, targeting companies with complementary technologies[31]. - The company aims to achieve a revenue target of 5,000 million for the next fiscal year, representing a growth target of approximately 26.5%[176]. - The company is exploring potential acquisitions to enhance its service offerings, with a budget of 500 million yuan allocated for this purpose[183]. Research and Development - The company is investing in R&D for new technologies, particularly in AI and AR, with a budget allocation of approximately $10 million for the next fiscal year[30]. - Research and development expenses increased by 74.28% to ¥159,270,126.29 compared to the previous year[97]. - The company has launched several key R&D projects, including a SaaS platform for data management and an AI middle platform for unified AI capabilities[98][99]. - The company has increased its R&D personnel from 199 in 2024 to 298 in 2025, representing a growth of 49.75%[101]. - The company aims to optimize its zMaticoo recommendation algorithm and RTB advertising algorithm to strengthen its advertising platform's technical capabilities[79]. Advertising and Marketing Innovations - In 2025, the company achieved a significant transition from "full-link automation" to "full-scenario autonomy" with the launch of the AI Drive 2.0 smart marketing solution[8]. - The programmatic advertising platform zMaticoo underwent a qualitative leap, completing the private deployment of the DeepSeek-R1 model and achieving a comprehensive upgrade to SDK&DSP 2.0[9]. - The AI-driven marketing solution, AI Drive 2.0, aims to automate marketing processes and enhance ROI for clients[64]. - The integration of AI technology is expected to reshape the entire digital marketing chain, driving significant industry transformation[64]. - The company has established deep partnerships with major media platforms such as Google, Meta, TikTok, and Microsoft Advertising, enhancing its global media resource advantage[65]. Corporate Governance and Management - The company has established a robust corporate governance structure, complying with relevant laws and regulations to protect the rights of all shareholders, especially minority shareholders[158]. - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[161]. - The company has implemented a transparent performance evaluation system for senior management, with a dedicated compensation and assessment committee[162]. - The company is committed to maintaining the legal rights of all shareholders, particularly minority shareholders[189]. - The company has established an independent business operation capability and a complete operational system, ensuring independence from the controlling shareholder in assets, business, personnel, institutions, and finance[160]. Employee Development and Training - The total number of employees at the end of the reporting period was 1,114, with 1,153 employees receiving salaries during the period[196]. - The company conducted 58 training sessions covering 4,093 participants, with a training satisfaction score of 9.5, the highest in history[199]. - The company has implemented a digital learning platform with over 1,200 courses, achieving an 82% mobile learning rate[199]. - The employee composition includes 567 production staff, 109 sales personnel, 298 technical staff, and 31 financial staff[196]. - The new long-term incentive plan aims to align the interests of core talent with the company's value growth, enhancing the performance-based compensation mechanism[198]. Risks and Challenges - The company faces risks related to innovation, market competition, and changes in overseas market environments, which could impact long-term business development[133][134][135]. - The company prioritizes data protection and anonymization to prevent misuse of user information, which is critical for maintaining its reputation and operational integrity[138]. - The company faces risks related to data resource acquisition limitations and storage security, which could adversely affect operational performance if data collection is restricted by partners or regulations[139]. - International trade tensions and changes in the global environment could negatively impact the company's performance, particularly if significant trade disputes arise[144]. Financial Management and Investments - The company has established a market value management system to enhance investor returns and maintain investor interests, approved on August 15, 2025[148]. - The company has implemented a risk management system for foreign exchange hedging, including regular reviews of exchange rate exposure and strategy adjustments[121]. - The company does not engage in speculative derivative investments, focusing solely on hedging to mitigate exchange rate risks[122]. - The company’s financial shared center manages all foreign exchange hedging activities to prevent speculative trading[121]. - The company has reported a total of 2,684,879 million in financing funds, indicating strong liquidity[118].

Financial Performance - The company reported R&D expenses of CNY 976.96 million for the reporting period, an increase of 24.79% compared to the same period last year[3]. - The company raised a net amount of CNY 3,303.43 million during its IPO on the Shanghai Stock Exchange in January 2022[4]. - The company plans not to distribute cash dividends or issue new shares for the 2025 fiscal year due to accumulated losses of CNY -3,775.58 million in the parent company[12][13]. - The company's operating revenue for 2025 reached ¥662,515,554.62, a significant increase of 231.62% compared to ¥199,781,622.22 in 2024[32]. - The net loss attributable to shareholders decreased to ¥969,333,663.43 in 2025 from ¥1,043,919,217.28 in 2024, reflecting a reduction of ¥74,586,553.85[35]. - The sales revenue from pharmaceutical products amounted to ¥249,723,500, which is a 72.71% increase from ¥144,592,000 in the previous year[35]. - The cash flow from operating activities showed a net outflow of ¥290,223,166.42, which is an improvement compared to the outflow of ¥956,443,630.18 in 2024[32]. - The company's total assets increased by 6.56% to ¥4,555,842,397.99 at the end of 2025, compared to ¥4,275,508,853.05 in 2024[32]. - The net assets attributable to shareholders decreased by 77.72% compared to the previous year, primarily due to high R&D investments[36]. - The company reported a net profit attributable to shareholders of -¥969,223,418.62 for 2025, a slight improvement from -¥1,015,103,374.38 in 2024, but a decline from -¥935,228,300.47 in 2023[47]. Research and Development - The company has 14 key products in various stages of development, including 10 innovative drugs and 4 biosimilars, focusing on oncology and age-related diseases[3]. - The company anticipates continued high R&D expenditures in the coming years, with projected expenses of CNY 835.78 million, CNY 782.87 million, and CNY 976.96 million for 2023, 2024, and 2025, respectively[5]. - The company emphasizes the importance of clinical value in drug development, aligning with recent regulatory guidelines to ensure patient-centered outcomes[8]. - The company is investing in R&D for new therapies targeting autoimmune diseases, with a budget increase of 15% for the upcoming fiscal year[22]. - The company has developed and launched several monoclonal antibody injection products, including 9MW0311 (Mairishu®) and 9MW0321 (Mairuijian®)[20]. - The company is actively involved in the development of antibody-drug conjugates, including 9MW2821 (Bulumtatug Fuvedotin) and 9MW2921[20]. - The company has independently undertaken a major national project for new drug creation and is involved in multiple national key R&D programs, enhancing its innovation capabilities[57]. - The company has filed 69 new invention patent applications and received 18 new invention patent grants during the reporting period, bringing the total to 355 applications and 90 granted patents[57]. Product Development and Pipeline - The company has 4 products that have entered the commercialization stage, which is expected to improve its financial condition and help achieve profitability[4]. - The product pipeline includes a mix of preclinical, clinical research, and registered products, indicating a robust development strategy[58]. - The company is advancing its 9MW2821 (ADC) product for Nectin-4, with a mid-analysis expected in H2 2026 and Pre-NDA submission anticipated in the same period[60]. - The company has multiple ongoing clinical trials, including a Phase II trial for triple-negative breast cancer, expected to complete in 2024[60]. - The company is focusing on expanding its oncology pipeline, with several products in various stages of clinical trials, including esophageal cancer and lung cancer[60]. - The company is collaborating with multiple partners for its products, enhancing its market reach and development capabilities[60]. - The company is in the process of developing new therapies for various cancers, with a focus on innovative ADC technologies[60]. - The company is actively pursuing regulatory approvals for its pipeline products, indicating a robust strategy for future growth[60]. Market and Competitive Landscape - The global oncology drug market is projected to grow from $143.5 billion in 2019 to $253.3 billion by 2024, with a CAGR of 12.0%[177]. - The Chinese oncology drug market is expected to increase from $26.4 billion in 2019 to $35.9 billion by 2024, with a CAGR of 6.3%[177]. - The ADC market is anticipated to grow from $2.8 billion in 2019 to $14.1 billion by 2024, reflecting a CAGR of 37.9%[184]. - The Chinese ADC market is projected to expand from $500 million in 2024 to $1 billion in 2025, reaching $14.1 billion by 2032, with a CAGR of 45.9%[184]. - The market for RANKL monoclonal antibodies for treating giant cell tumor of bone (GCTB) is projected to grow from $1.049 billion in 2024 to $2.408 billion by 2028, with a CAGR of 23.1%[199]. - The market for RANKL monoclonal antibodies for osteoporosis treatment is expected to increase from $1.317 billion in 2024 to $4.694 billion by 2028, with a CAGR of 31.6%[199]. Regulatory and Compliance - The company is committed to maintaining compliance with cGMP standards to ensure the quality and safety of its products[22]. - The NHSA aims to implement a disease-based payment management system to enhance the efficiency of medical insurance fund payments and support high-quality development of medical institutions[174]. - The NHSA introduced a commercial health insurance directory for innovative drugs, including 19 high-priced innovative drugs, to support their development[174]. - The Ministry of Industry and Information Technology emphasized the need for the pharmaceutical industry to focus on innovation and enhance the resilience and safety of the pharmaceutical supply chain[175]. Strategic Partnerships and Collaborations - The company has established a partnership with Qilu Pharmaceutical in June 2025, with a contract value of up to 500 million RMB, including a non-refundable upfront payment of 380 million RMB[81]. - The company has signed formal cooperation agreements with 31 countries for 9MW0311 and submitted registration applications in eight countries, including Pakistan, which has already granted approval[70][71]. - The company has signed a strategic cooperation agreement with Ping An Good Doctor to create an integrated online and offline solution for bone health and autoimmune disease management, enhancing patient access to quality medical resources[162]. Challenges and Risks - The company has accumulated losses and will face potential risks, including reliance on external financing for operational cash flow, which may impact R&D and talent acquisition[4]. - The company faces risks related to the approval of its biosimilar product 9MW0813, which is currently under review and could impact sales revenue if not approved[6]. - The company is exposed to risks from centralized procurement policies that could lower the sales prices and gross margins of its biological products[7].

Financial Performance - The company's operating revenue for 2025 reached ¥24,353,884,352.94, representing an increase of 8.72% compared to ¥22,401,181,999.32 in 2024[20] - Net profit attributable to shareholders for 2025 was ¥1,013,445,450.94, a growth of 4.38% from ¥970,956,088.36 in 2024[20] - The net profit after deducting non-recurring gains and losses was ¥752,391,294.66, which is a decrease of 10.07% compared to ¥836,646,676.09 in 2024[20] - The net cash flow from operating activities decreased by 47.28% to ¥661,554,052.09 from ¥1,254,731,330.93 in 2024[20] - Basic earnings per share for 2025 were ¥1.48, up 4.96% from ¥1.41 in 2024[20] - Total assets at the end of 2025 amounted to ¥26,139,002,985.08, reflecting a 15.30% increase from ¥22,670,281,213.89 at the end of 2024[20] - The net assets attributable to shareholders increased by 5.06% to ¥13,338,609,370.67 from ¥12,695,710,662.70 in 2024[20] - The company reported a significant increase in production volume for liquid crystal display main control boards, with a production increase of 3.33% year-on-year[129] - The gross profit margin for the overall business was 20.04%, showing a slight decrease of 1.29% compared to the previous year[128] Market Position and Growth - The company has established a leading position in the interactive display market, particularly in educational and corporate service scenarios[29] - The company achieved a 49.8% market share in the domestic IFPD education market for its Seewo interactive smart panel, maintaining its leading position for 14 consecutive years[43] - The MAXHUB interactive smart panel holds a 27.3% market share in the domestic IFPD conference market, continuing its leadership for 9 years[46] - The company's recording market share in the education sector is projected to reach 33.9% by 2025, an increase of approximately 4.8 percentage points compared to the previous period, solidifying its leading position for the fourth consecutive year[55] - The company’s digital signage solutions have been widely adopted across various industries, including manufacturing and finance, enhancing information dissemination in public spaces[49] - The company’s LED display products utilize advanced packaging technologies and are designed to meet high-end visual display needs across various commercial applications[51] - The company has launched a new series of video conferencing terminals, including the Xcore Kit in 2024 and the BM45 omnidirectional microphone in 2025, enhancing its product lineup for cloud conferencing solutions[57] - The company has established subsidiaries in 10 countries and localized teams in 29 countries to provide tailored smart collaboration solutions for global enterprises[99] Research and Development - The company invested 1.602 billion yuan in R&D, accounting for 6.58% of its annual revenue[115] - The company filed over 1,300 patent applications during the reporting period, with more than 70% being invention patents[115] - The company has implemented a three-generation rolling R&D mechanism to drive product and service upgrades through technological innovation[30] - The company has developed a 16-microphone linear array technology to enhance audio pickup quality, utilizing AI noise reduction and echo cancellation techniques[39] - The company has launched a new air conditioning variable frequency compressor and motor drive technology, enhancing product competitiveness and energy efficiency under extreme conditions[142] - The company is focusing on optimizing audio and video interaction experiences through continuous algorithm improvements and product matrix enhancements[140] - The company is committed to maintaining industry-leading levels in algorithm accuracy while enhancing user experience through offline large model services[143] Strategic Initiatives - The company plans to release the next generation AI teaching partner, "Seewo Super Energy Xiaoxi," by December 2025, marking a significant advancement in its AI capabilities[80] - The company aims to leverage artificial intelligence to transform educational practices, aligning with national policies promoting digital education and AI integration in teaching[75] - The company has established strategic cooperation with UNESCO to support smart classroom construction in multiple countries and provide modern teaching skills training for teachers in 53 countries[78] - The company aims to support over 1 million teachers in online training by 2025, covering more than 30,000 schools across 1,200 districts[87] - The company has activated over 1 million users for its AI lesson preparation tool, with 19 key application demonstration areas established for the Xiwo Classroom Intelligent Feedback System[91] - The company is focusing on the integration of hardware and software in teaching processes, enhancing the closed-loop value from assignment data to teaching improvement[141] Financial Management and Investments - The total investment amount surged by 184.69% from ¥2,101,610,185.85 in the previous year to ¥5,983,055,794.97 in the current reporting period[156] - The company reported a significant decrease in net cash flow from investment activities, with a net outflow of -¥3,280,770,257.95, compared to -¥428,853,287.89 in the previous year, reflecting a 665.01% change[146] - The company has established a strong supply chain collaboration, optimizing various information systems for efficient management across all business processes[116] - The company has implemented strict risk control measures for foreign exchange hedging, including matching hedging activities with core business[166] - The company has established an internal control system for financial derivative trading to mitigate risks associated with foreign exchange hedging[166] Corporate Governance - The company held two shareholder meetings during the reporting period, ensuring compliance with relevant regulations and facilitating communication with shareholders[188] - The board of directors consists of 9 members, including 3 independent directors, and has held 6 meetings during the reporting period, adhering to legal and regulatory requirements[190] - The company maintains independence from its actual controller in terms of assets, personnel, finance, and operations, ensuring a complete business system[192] - The company has established independent operational capabilities and possesses necessary assets for its business, including land use rights and intellectual property[193] - There are no instances of monetary funds or other assets being occupied by shareholders or related parties, nor does the company provide guarantees for shareholders and their related enterprises[195]